Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 245

Similar articles for PubMed (Select 15161667)

1.

The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.

Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G.

Blood. 2004 Sep 15;104(6):1825-32. Epub 2004 May 25.

2.

Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.

Kobune M, Chiba H, Kato J, Kato K, Nakamura K, Kawano Y, Takada K, Takimoto R, Takayama T, Hamada H, Niitsu Y.

Mol Cancer Ther. 2007 Jun;6(6):1774-84.

3.

Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells.

Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM.

J Biol Chem. 2002 May 3;277(18):15309-16. Epub 2002 Feb 11.

4.

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.

Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB.

Circ Res. 2002 Jul 26;91(2):143-50.

5.

Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation.

Lee MH, Cho YS, Han YM.

Stem Cells. 2007 Jul;25(7):1654-63. Epub 2007 Apr 26.

6.
7.

Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.

Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, Ozawa K.

Oncogene. 2009 Jan 15;28(2):231-42. doi: 10.1038/onc.2008.385. Epub 2008 Oct 13.

PMID:
18850009
8.

Synergistic antimyeloma effects of zoledronate and simvastatin.

Schmidmaier R, Simsek M, Baumann P, Emmerich B, Meinhardt G.

Anticancer Drugs. 2006 Jul;17(6):621-9.

PMID:
16917207
9.

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.

Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.

Br J Haematol. 2007 Feb;136(3):414-23. Epub 2006 Dec 14.

PMID:
17173546
10.

HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.

Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C.

Biochem Biophys Res Commun. 2008 Sep 19;374(2):309-14. doi: 10.1016/j.bbrc.2008.07.012. Epub 2008 Jul 14.

PMID:
18625202
11.

Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins.

Degraeve F, Bolla M, Blaie S, Créminon C, Quéré I, Boquet P, Lévy-Toledano S, Bertoglio J, Habib A.

J Biol Chem. 2001 Dec 14;276(50):46849-55. Epub 2001 Oct 8.

12.

Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways.

Nagaoka T, Hein TW, Yoshida A, Kuo L.

Invest Ophthalmol Vis Sci. 2007 Feb;48(2):825-32.

PMID:
17251484
13.

Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.

Ishibashi T, Nagata K, Ohkawara H, Sakamoto T, Yokoyama K, Shindo J, Sugimoto K, Sakurada S, Takuwa Y, Teramoto T, Maruyama Y.

Biochim Biophys Acta. 2002 Jun 12;1590(1-3):123-30.

14.

Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells.

Itoh Y, Kimoto K, Imaizumi M, Nakatsuka K.

Exp Eye Res. 2007 Mar;84(3):464-72. Epub 2007 Jan 10.

PMID:
17217948
15.
16.

Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway.

Yamashita M, Otsuka F, Mukai T, Otani H, Inagaki K, Miyoshi T, Goto J, Yamamura M, Makino H.

J Endocrinol. 2008 Mar;196(3):601-13. doi: 10.1677/JOE-07-0532.

17.

HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways.

Rupérez M, Rodrigues-Díez R, Blanco-Colio LM, Sánchez-López E, Rodríguez-Vita J, Esteban V, Carvajal G, Plaza JJ, Egido J, Ruiz-Ortega M.

Hypertension. 2007 Aug;50(2):377-83. Epub 2007 Jun 25.

18.

Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway.

Kozai T, Eto M, Yang Z, Shimokawa H, Lüscher TF.

Cardiovasc Res. 2005 Dec 1;68(3):475-82. Epub 2005 Aug 11.

19.

Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia.

Bi X, Baudry M, Liu J, Yao Y, Fu L, Brucher F, Lynch G.

J Biol Chem. 2004 Nov 12;279(46):48238-45. Epub 2004 Sep 9.

20.

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.

Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS.

Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8301-5. Epub 2002 Jun 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk